Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

15.04.25 15:40 Uhr

Werte in diesem Artikel
Aktien

21,86 USD -0,47 USD -2,10%

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adma Biologics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).Over the past three months, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.Our latest available data shows that ADMA has returned about 21.9% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.8% on a year-to-date basis. This shows that Adma Biologics is outperforming its peers so far this year.Another stock in the Medical sector, Agilon Health (AGL), has outperformed the sector so far this year. The stock's year-to-date return is 194.7%.The consensus estimate for Agilon Health's current year EPS has increased 22.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 509 individual stocks and currently sits at #75 in the Zacks Industry Rank. This group has lost an average of 6.4% so far this year, so ADMA is performing better in this area.Agilon Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #80. The industry has moved -0.5% so far this year.Adma Biologics and Agilon Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis Report Agilon Health, Inc. (AGL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf ADMA Biologics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf ADMA Biologics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu ADMA Biologics Inc

Wer­bung

Analysen zu ADMA Biologics Inc

DatumRatingAnalyst
15.04.2019ADMA Biologics BuyH.C. Wainwright & Co.
07.02.2019ADMA Biologics BuyH.C. Wainwright & Co.
11.12.2017ADMA Biologics BuyMaxim Group
23.01.2017ADMA Biologics BuyMaxim Group
13.05.2015ADMA Biologics BuyMaxim Group
DatumRatingAnalyst
15.04.2019ADMA Biologics BuyH.C. Wainwright & Co.
07.02.2019ADMA Biologics BuyH.C. Wainwright & Co.
11.12.2017ADMA Biologics BuyMaxim Group
23.01.2017ADMA Biologics BuyMaxim Group
13.05.2015ADMA Biologics BuyMaxim Group
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für ADMA Biologics Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen